Lead Product(s) : Tizanidine HCl
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : National Institutes of Health
Deal Size : $2.5 million
Deal Type : Funding
Details : Proceeds from the financing will be used for the advancement of the company’s tizanidine implant product (DLP-208) for moderate-severe spasticity. DLP-208 can provide sustained therapy for several months, while only requiring a 10-minute procedure in a...
Brand Name : DLP-208
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 16, 2021
Lead Product(s) : Tizanidine HCl
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : National Institutes of Health
Deal Size : $2.5 million
Deal Type : Funding
Lead Product(s) : Hyaluronic Acid,Type II Collagen,Polysaccharide
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Bioiberica
Deal Size : Undisclosed
Deal Type : Partnership
Details : Nestlé Health Science is incorporating Bioiberica’s patented ingredient, Mobilee®, into its MERITENE® Mobilis® joint-health drink mix.
Brand Name : Meritene Mobilis
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 16, 2020
Lead Product(s) : Hyaluronic Acid,Type II Collagen,Polysaccharide
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Bioiberica
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Epicatechin
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The company's prior studies have shown that EB 002 can stimulate mitochondrial biogenesis, contributing to the restoration of tissue bioenergetics, thus upregulating key protein production.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 14, 2020
Lead Product(s) : Epicatechin
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Autologous adipose-derived regenerative cells
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Study reveals favorable results using regenerative cells isolated from patients’ own body fat prepared with the Transpose® RT System in the Journal of Orthopaedic Surgery and Research.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
April 07, 2020
Lead Product(s) : Autologous adipose-derived regenerative cells
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Chondrocytes
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Biosolution
Deal Size : Undisclosed
Deal Type : Agreement
Mundipharma, Biosolution to market CartiLife in South Korea
Details : Under the agreement, Mundipharma obtains the rights to market and distribute CartiLife® in South Korea.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 06, 2020
Lead Product(s) : Chondrocytes
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Biosolution
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?